Your session is about to expire
← Back to Search
Other
Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Phase 1
Waitlist Available
Led By Joe Stanfield, PhD
Research Sponsored by Healthpoint
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Healthy subjects
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48-hours post irradiation
Awards & highlights
No Placebo-Only Group
Summary
The product is being tested to see if exposure to light causes photoallergic reactions on the skin.
Eligible Conditions
- Healthy Subjects
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48-hours post irradiation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48-hours post irradiation
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Frequency Distribution of Skin Irritation Scores
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: XenadermExperimental Treatment2 Interventions
Subject serves as own control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trypsin
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
HealthpointLead Sponsor
35 Previous Clinical Trials
3,073 Total Patients Enrolled
Joe Stanfield, PhDPrincipal InvestigatorSuncare Research Laboratories